Category Archives: Pr Newswire

DIFC continues to drive the future of finance with outstanding H1 2024 results

DUBAI, UAE, July 30, 2024 /PRNewswire/ — The Dubai International Financial Centre (DIFC), the leading global financial centre in MEASA region, announced outstanding results for the first half of 2024. Coinciding with its 20th anniversary, the results reinforce DIFC’s growing role in driving the future of finance, and Dubai’s position as a top global ecosystem for […]

Hugging Every Fun Thought! Haivivi Unveils the World’s First AIGC Toy, BubblePal

SHENZHEN, China, July 30, 2024 /PRNewswire/ — With the rapid advancement of AI technology, toys, one of humanity’s greatest inventions driven by natural instincts, are now encountering new development opportunities. On June 25th, emerging AI toy innovator Haivivi officially launched the world’s first interactive talking toy based on AIGC technology—BubblePal. Leveraging its cutting-edge AI technology and […]

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the […]

Earth Science Tech, Inc., Reports its June 30, 2024, Quarter Results, Recording Over $8.5M in Revenue and $1.07M in Net Profit

Miami, FL, July 29, 2024 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a holding entity currently focused on the health and wellness industry, today shares its financial results from its quarter ended June 30, 2024. For the three-month quarter ended June 30, 2024, the Company recorded: $1,384,407 in Cash, versus $91,989 […]

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on […]

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will provide a corporate update and […]

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), […]

Acclime unveils new commercial leadership structure for next phase of growth

SINGAPORE, July 30, 2024 /PRNewswire/ — Acclime, providing businesses with corporate, governance and advisory services globally, is proud to announce a new regional commercial leadership structure which sets the foundation for the next stage of growth for the company. This move underscores Acclime’s commitment to enhancing operational efficiency and regional expertise across its expansive network […]

TheLotter Australia expands its offerings with the launch of a new mobile app

Leading online lottery service provider enables Australians to enter international lottery draws online SYDNEY, July 30, 2024 /PRNewswire/ — TheLotter Australia is excited to announce a new addition: a user-friendly mobile app, available for both iOS and Android devices. This extension complements the already popular website, offering Australians a simple way to join the world’s […]

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis […]